Ticker > Company >

Unjha Formulations share price

Unjha Formulations Ltd.

BSE: 531762 SECTOR: Pharmaceuticals & Drugs  9446   25   1

31.25
+0.75 (2.46%)
BSE: 20 Dec 04:00 PM

Price Summary

Today's High

₹ 32.19

Today's Low

₹ 29.5

52 Week High

₹ 39

52 Week Low

₹ 15.01

FinStar is Suspended!

FinStar can not be assigned to this company due to its dicey outlook and insufficient data. We will update the FinStar for this company as soon as the data is updated from its end.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

14 Cr.

Enterprise Value

13.13 Cr.

No. of Shares

0.45 Cr.

P/E

17.46

P/B

4.22

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  7.41

CASH

0.87 Cr.

DEBT

0 Cr.

Promoter Holding

36.92 %

EPS (TTM)

₹  1.79

Sales Growth

40.61%

ROE

10.72 %

ROCE

19.53%

Profit Growth

-1.63 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year40.61%
3 Year22.93%
5 Year10.12%

Profit Growth

1 Year-1.63%
3 Year38.97%
5 Year-1.54%

ROE%

1 Year10.72%
3 Year11.76%
5 Year11.88%

ROCE %

1 Year19.53%
3 Year19.14%
5 Year21.96%

Debt/Equity

0

Price to Cash Flow

13.65

Interest Cover Ratio

9.3051

CFO/PAT (5 Yr. Avg.)

0.598679029816742

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 36.92 0.00
Jun 2024 36.92 0.00
Mar 2024 36.92 0.00
Dec 2023 36.92 0.00
Sep 2023 36.92 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good revenue growth of 22.9347638255096% for the Past 3 years.
  • Company is virtually debt free.
  • The company has an efficient Cash Conversion Cycle of 14.2542 days.

 Limitations

  • The company has a low EBITDA margin of 2.93720650841615% over the past 5 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 4.77 5.55 4.44 3.95 3.81
Total Expenditure 4.87 5.14 4.37 3.23 3.89
Operating Profit -0.09 0.41 0.07 0.72 -0.09
Other Income 0 0 0 0 0
Interest 0 0 0.05 0 0
Depreciation 0.02 0.02 0.02 0.02 0.02
Exceptional Items 0 0 0 0 0
Profit Before Tax -0.12 0.39 0 0.7 -0.11
Tax 0 0 0.17 0 0
Profit After Tax -0.12 0.39 -0.18 0.7 -0.11
Adjusted EPS (Rs) -0.26 0.87 -0.39 1.56 -0.24

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 10.6 9.96 14.16 13.15 18.5
Total Expenditure 10.35 9.59 13.84 12.72 17.92
Operating Profit 0.25 0.36 0.32 0.43 0.58
Other Income 0.26 0.22 0.19 0.03 0.01
Interest 0.12 0.17 0.13 0.06 0.05
Depreciation 0.08 0.08 0.08 0.08 0.08
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.31 0.33 0.3 0.33 0.45
Tax 0 0.23 0.05 0.05 0.17
Net Profit 0.31 0.1 0.25 0.28 0.28
Adjusted EPS (Rs.) 0.69 0.23 0.56 0.63 0.62

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 4.48 4.48 4.48 4.48 4.48
Total Reserves -2.67 -2.56 -2.31 -2.03 -1.75
Borrowings 0 0 0 0 0
Other N/C liabilities 0 0 0 0 0.01
Current liabilities 1.9 1.61 1.28 0.96 2.2
Total Liabilities 3.72 3.53 3.45 3.41 4.93
Assets
Net Block 1.14 1.12 1.07 1.1 1.12
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0 0
Loans & Advances 0 0 0 0 0
Other N/C Assets 0 0 0 0 0
Current Assets 2.57 2.4 2.38 2.31 3.81
Total Assets 3.72 3.53 3.45 3.41 4.93
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 0.31 0.1 0.25 0.33 0.45
Adjustment 0.2 0.25 0.21 0.13 0.13
Changes in Assets & Liabilities 0.01 -0.89 -0.05 -0.67 0.49
Tax Paid 0 0 0 -0.05 -0.05
Operating Cash Flow 0.39 -0.7 0.28 -0.26 1.03
Investing Cash Flow -0.1 -0.06 -0.02 -0.1 -0.11
Financing Cash Flow 0 0 0 -0.06 -0.05
Net Cash Flow 0.29 -0.77 0.26 -0.42 0.86

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 36.92 36.92 36.92 36.92 36.92
jashodaben shambhubhai pa... 16.51 16.51 16.51 16.51 16.51
krutiben mayankkumar pate... 14.89 14.89 14.89 14.89 14.89
neenaben urveshkumar pate... 1.90 - 1.90 1.90 1.90
urveshkumar shambhbhai pa... - - - - 3.62
urveshkumar shambhubhai p... 3.62 3.62 3.62 3.62 -
neeneben urveshkumar pate... - 1.90 - - -
PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 63.08 63.08 63.08 63.08 63.08
deep mayank patel - - - - 1.29
esha mayank patel 1.60 - 1.60 1.60 1.60
jatinkumar babulal patel 1.06 1.06 1.06 1.06 1.06
manish patel - 1.13 1.25 1.32 1.32
narveer yadav 1.17 1.17 1.17 1.17 1.17
deep mayankbhai patel 1.16 1.29 1.29 1.29 -
dheeraj kumar lohia - 1.15 - - -
esha mayank patel - 1.60 - - -
dheeraj kumar lohia 1.15 - - - -

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

Unjha Formulations - Quaterly Results 8 Nov, 1:48 PM Unjha Formulations - Quaterly Results 8 Nov, 1:48 PM Unjha Formulations - Quaterly Results 8 Nov, 1:48 PM Unjha Formulations informs about compliance certificate 11 Oct, 5:34 PM Unjha Formulations - Quaterly Results 1 Aug, 2:24 PM Unjha Formulations - Quaterly Results 1 Aug, 2:24 PM Unjha Formulations - Quaterly Results 1 Aug, 2:24 PM Unjha Formulations - Quaterly Results 17 May, 3:18 PM Unjha Formulations - Quaterly Results 17 May, 3:18 PM Unjha Formulations - Quaterly Results 17 May, 3:18 PM Unjha Formulations informs about board meeting 8 May, 5:20 PM Unjha Formulations - Quaterly Results 29 Jan, 2:06 PM Unjha Formulations - Quaterly Results 29 Jan, 2:06 PM Unjha Formulations - Quaterly Results 29 Jan, 2:06 PM Unjha Formulations - Quaterly Results 4 Aug, 2:31 PM Unjha Formulations - Quaterly Results 4 Aug, 2:31 PM Unjha Formulations - Quaterly Results 4 Aug, 2:31 PM Unjha Formulations - Quaterly Results 10 May, 3:01 PM Unjha Formulations - Quaterly Results 10 May, 3:01 PM Unjha Formulations - Quaterly Results 10 May, 3:01 PM Unjha Formulations informs about change in promoters shareholding 14 Mar, 1:00 PM Unjha Formulations - Quaterly Results 10 Feb, 1:20 PM Unjha Formulations - Quaterly Results 10 Feb, 1:20 PM Unjha Formulations - Quaterly Results 10 Feb, 1:20 PM Unjha Formulations - Quaterly Results 10 Nov, 1:10 PM Unjha Formulations - Quaterly Results 10 Nov, 1:10 PM Unjha Formulations - Quaterly Results 4 Aug, 1:29 PM Unjha Formulations - Quaterly Results 4 Aug, 1:29 PM Unjha Formulations - Quaterly Results 4 Aug, 1:29 PM Unjha Formulations informs about book closure 13 Jul, 4:08 PM Unjha Formulations - Quaterly Results 2 May, 2:40 PM Unjha Formulations - Quaterly Results 2 May, 2:40 PM Unjha Formulations - Quaterly Results 2 May, 2:40 PM Unjha Formulations informs about board meeting intimation 18 Apr, 4:47 PM Unjha Formulations - Quaterly Results 4 Feb, 1:24 PM Unjha Formulations - Quaterly Results 4 Feb, 1:24 PM Unjha Formulations - Quaterly Results 4 Feb, 1:24 PM Unjha Formulations informs about filing of distribution schedule 28 Aug, 2:35 PM Unjha Formulations informs about outcome of board meeting 23 Mar, 3:23 PM Unjha Formulations informs about board meeting 17 Mar, 11:09 AM Unjha Formulations informs about newspaper publication 10 Nov, 11:09 AM

Unjha Formulations Stock Price Analysis and Quick Research Report. Is Unjha Formulations an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Unjha Formulations and its performance over the period of time. Unjha Formulations stock price today is Rs 31.25.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Unjha Formulations cash from the operating activity was Rs 1.0261 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Unjha Formulations has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Unjha Formulations , the EPS growth was -1.6336 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Unjha Formulations has OPM of 3.11256487889272 % which is a bad sign for profitability.
     
  • ROE: Unjha Formulations have a average ROE of 10.7204 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Unjha Formulations is Rs 31.25. One can use valuation calculators of ticker to know if Unjha Formulations share price is undervalued or overvalued.
Last Updated on:
Brief about Unjha Formulations
X